The aims of this study were to i) reveal the population pharmacokinetics; and ii) assess the probability of target attainment (PTA) and cumulative fraction of response (CFR) (defined as the expected population PTA for a specific drug dose and a specific population of microorganisms) of imipenem in febrile neutropenic patients with bacteraemia. Ten patients were randomised into two groups: Group I received a 0.5-h infusion of 0.5 g of imipenem every 6 h (q6h) for 8 doses; and Group II received a 4-h infusion of 0.5 g q6h for 8 doses. A Monte Carlo simulation was performed to determine the PTA. The volume of distribution and total clearance of imipenem were 20.78 ± 1.35 l and 23.19 ± 1.34 l/h, respectively. Only a 4-h infusion of 1 g q6h regimen achieved a PTA >93% for 80% T >MIC for a MIC of 2 mg/ml. A 4-h infusion of all simulated regimens and a 0.5-h infusion of 0.5 g q6h and 1 g q6h achieved targets (CFR ! 90%) against Escherichia coli and Klebsiella spp. However, against Pseudomonas aeruginosa and Acinetobacter spp., no regimens achieved their targets. In conclusion, the results indicate that a higher than manufacturer's dosage recommendation is required to maximize the activity of imipenem.
Introduction
Carbapenems, a class of antimicrobial agents providing a broad spectrum of activity against Gram-negative, Gram-positive and anaerobic bacteria, are widely prescribed in critically ill patients with severe infections. Imipenem, a carbapenem antibiotic, is one of the most crucial antibiotics used for coverage of some highly resistant pathogens (1) . In common with other b-lactams, this agent exhibits primarily time-dependent antimicrobial activity and the pharmacokinetics/pharmacodynamics (PK/PD) index that best predicts the in vivo antimicrobial activity is the exposure time during which the plasma concentration remains above the minimum inhibitory concentration (T >MIC ) of the pathogens (2, 3) .
In critically ill patients with severe sepsis, the early use of an appropriate antimicrobial agent in terms of spectrum of antimicrobial activity are known to be the major factors for successful treatment, leading to a lower mortality rate for patients than less efficacious treatment regimens (4) . Moreover, altered PK patterns have been found with several hydrophilic antimicrobial agents used in critically ill patients with febrile neutropenia when compared with healthy subjects, resulting in fluctuation of the plasma concentrations of the drug and thus affecting the achievement of the desired pharmacodynamic targets for effective antimicrobial therapy (5, 6) . Another previous study also found that the total clearance (CL) of imipenem was significantly lower and the volume of distribution (Vd) significantly larger in this patient population than in normal volunteer populations (7) . Therefore, the aims of this study were to i) study the population PK of imipenem, and ii) assess the probability of target attainment (PTA) and cumulative fraction of response (CFR) of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia in order to optimize a dosage regimen.
Materials and methods

Subjects
The study was conducted in patients with febrile neutropenia and bacteraemia. Patients were eligible for the study if they met the following criteria: (i) age >18 years; (ii) body temperature !38.3 C;
(iii) neutrophil count <500 cells/ml; and (iv) having bacteraemia, confirmed by at least one positive blood culture. Patients were excluded from the study if they were pregnant or in circulatory shock (defined as a systolic blood pressure of <90 mmHg and poor tissue perfusion) or had documented hypersensitivity to imipenem or an estimated creatinine clearance (CL Cr ) (determined by the CockcrofteGault method) (8) of <50 ml/min. MICs were determined by E test. The protocol for the study was approved by the Ethics Committee of Songklanagarind Hospital and written informed consent was obtained from each subject before enrolment.
Drugs and chemicals
Imipenem (Tienam
®
) was purchased from MSD, Thailand. Imipenem standard powder was generously donated by Merck & Co, Inc., USA. All the solvents were of high-performance liquid chromatography (HPLC) grade.
Study design
The patients were allocated by simple randomization into two groups using blinded opaque envelope selection. Group I received a 0.5-h infusion of 0.5 g of imipenem diluted in 100 ml of normal saline solution via an infusion pump at a constant flow rate every 6 h (q6h) for 8 doses, and Group II received a 4-h infusion of 0.5 g of imipenem diluted in 100 ml of normal saline solution via an infusion pump at a constant flow rate q6h for 8 doses. A Monte Carlo simulation (MCS) was performed to predict the PTAs determining the efficacy of various dosage regimens (0.5 g q6h, 1 g q6h, 0.5 g q8h and 1 g q8h) of imipenem. All imipenem doses were given at room temperature (32e37 C), and after completion of the 2-day study regimen, all patients were still treated with imipenem for 11 more days to complete their full 14-day course of treatment.
Blood sampling
The imipenem PK studies were carried out during administration of the eighth dose of each regimen. Blood samples (ca. 3 ml) were obtained by direct venipuncture at the following times: shortly before beginning the dosage regimens (time 0) and then at 0.25, 0.5, 0.75, 1, 2, 3, 4, 5 and 6 h after the eighth dose of a 0.5-h infusion and shortly before beginning the dosage regimens (time 0) and then at 0.5, 1, 2, 3, 4, 4.5, 5, 5.5 and 6 h after the eighth dose of a 4-h infusion. All blood samples were transferred to a heparinised tube, immediately stored on ice, and centrifuged at 1000Â g at 4 C for 10 min within 5 min. An equal volume of stabilising solution [0.5 M 3-(N-morpholino) propanesulfonic acid (MOPS)/water/ ethylene glycol, 2:1:1, v/v/v] was added to each plasma sample, and the mixture was then vortexed and stored at À80 C until analysis within 1 week.
Imipenem assay
This assay was used for measuring imipenem concentrations only, not for cilastatin concentrations. The concentrations of imipenem were determined by reversed-phase HPLC. The samples were prepared by the method of Garcia-Capdevila et al (9) . Briefly, 250 ml of the stabilizing solution was added to 250 ml of the sample.
Mixtures were then subjected to ultrafiltration, using Ultrafree ® -MC Centrifugal Filter Units, for 10 min at 6000 g. An aliquot of the sample (10 ml) was injected, using an automated injection system (Waters 717 plus Autosampler, Waters Associates, Milford, MA, USA), onto a Nova-Pak C18 column (Waters Associates). The mobile phase was 0.2 M borate buffer, pH 7.2, at a flow rate of 1 ml/min. The column effluent was monitored by UV detection (Waters 486, Waters Associates) at 300 nm. The peaks were recorded and integrated on a Waters 746 Data Module (Waters Associates). The limit of detection of imipenem was 0.125 mg/ml. The intra-assay reproducibility values characterized by coefficients of variation (CVs) were 1.84%, 0.02% and 0.95% for samples containing 1, 10 and 100 mg/ml, respectively. The inter-assay reproducibility precision values, calculated by CVs, were 2.60%, 4.75% and 2.18% for samples containing 1, 10 and 100 mg/ml, respectively.
PK analysis & Monte Carlo simulation
The 2-compartment model could not consistently describe the whole concentration-time profile obtained. We found that the 3-compartment infusion model could consistently describe the imipenem concentration-time profile. The differential equations describing the 3-compartment model were solved numerically by Taylor series expansion (10), using Visual Basic language in Microsoft Excel (Microsoft Excel 2003, Microsoft Corp). The summation of infinite series was calculated until converge. The method was validated to be consistent with Runge-Kutta order 4 method (10). Taylor series method is used to achieve better numerical stability with high pharmacokinetic rate parameters (i.e., stiff differential equations). PK parameters were obtained by nonlinear regression. The objective function to be minimized is the sum of square errors of logarithmic transformed data. The reason for logarithmic transformation is to enhance the reliability of the whole distribution phase which was used extensively in computing time above MIC. The optimization method is random heuristic optimization (11, 12) . The search parameters were permitted to random walk around the previous best result to achieve improved fit and repeat this process until converge. The method was repeated with different initial conditions to ascertain global convergence.
The Monte Carlo simulation (MCS) used in this study was written in the Basic language using the Quick Basic 3.0 compiler (Microsoft Corp) to calculate concentration-time profiles. BoxMuller Transformation was used to simulate the log-normal PK parameters (13) . A Choleski decomposition matrix, computed from covariate matrix (14) , was solved (and validated to be working properly) in Microsoft Excel was used for simulating new PK parameters dataset with the same covariates. All simulated parameters were validated for average, standard deviation and covariance to ensure there were no statistically significant differences between the simulated parameters and the actual parameters (Appendix A). The MCS was performed using at least 10,000 sets of simulated parameters to calculate the % target attainment at 40% and 80% T >MIC .
Minimum inhibitory concentration distributions and cumulative fraction of response
MIC distributions were derived from imipenem MIC 50 and MIC 90 (MICs for 50% and 90% of the organisms, respectively) and MIC ranges obtained from the European Committee on Antimicrobial Susceptibility Testing (EUCAST; updated 2 Oct 2013) for Escherichia coli, Klebsiella spp., Pseudomonas aeruginosa and Acinetobacter spp. isolates. MIC distributions were estimated from 16667 strains of E. coli, 29483 strains of Klebsiella spp., 64225 strains of P. aeruginosa and 6351 strains of Acinetobacter spp. The CFRs (defined as the expected population PTA for a specific drug dose and a specific population of microorganisms) were determined for each regimen against each population of E. coli, Klebsiella spp., P. aeruginosa and Acinetobacter spp. The optimal CFRs were defined as !90%.
Results
Ten febrile neutropenic patients were enrolled in the study (six males and four females), with a mean ± S.D. age of 38.8 ± 16.96 years (range 18e68 years) and a mean ± S.D. body weight of 58.35 ± 15.74 kg (range 27.7e87 kg). The characteristics of all patients and the MICs of imipenem for the isolated pathogens are shown in Table 1 . The population PK parameters of imipenem are shown in Table 2 . The mean ± S.D. of Vd and CL of imipenem in these patients were 20.78 ± 1.35 l and 23.19 ± 1.34 l/h, respectively. None of the tested covariates had any identifiable influence on the PK parameters (Appendix A). The PTAs for the 0.5-h and 4-h infusion regimens of imipenem achieving 40% T >MIC and 80% T >MIC at specific MICs are shown in Table 3 and Fig. 1 . For pathogens with a MIC of 2 mg/ml, the PTAs of achieving 40% T >MIC following administration of imipenem by a 0.5-h infusion of 0.5 g q6h, 1 g q6h, 0.5 g q8h and 1 g q8h were 69.68%, 97.15%, 37.22% and 87.31%, respectively and the PTAs of achieving 40% T >MIC following administration of imipenem by a 4-h infusion of 0.5 g q6h, 1 g q6h, 0.5 g q8h and 1 g q8h were 96.63%, 99.97%, 90.79% and 99.93%, respectively. For pathogens with a MIC of 4 mg/ml, the PTAs of achieving 40% T >MIC following administration of imipenem by a 4-h infusion of 0.5 g q6h, 1 g q6h, 0.5 g q8h and 1 g q8h were 29.07%, 96.58%, 12.12% and 91.11%, respectively. For pathogens with a MIC of 1 mg/ml, the PTAs of achieving 80% T >MIC following administration of imipenem by a 4-h infusion of 0.5 g q6h, 1 g q6h, 0.5 g q8h and 1 g q8h were 93.56%, 99.86%, 49.33% and 89.08%, respectively. For pathogens with a MIC of 2 mg/ml, the PTAs of achieving 80% T >MIC following administration of imipenem by a 4-h infusion of 0.5 g q6h, 1 g q6h, 0.5 g q8h and 1 g q8h were 34.77%, 93.60%, 4.45% and 49.28%, respectively. Assessment of CFR for the patients who achieved 40% T >MIC and 80% T >MIC with the imipenem regimens against E. coli, Klebsiella spp., P. aeruginosa and Acinetobacter spp. are shown in Table 4 . The predicted CFRs for PTA achieving a target of 40% T >MIC and 80% T >MIC for E. coli following administration of imipenem by all simulated regimens were >90%. The predicted CFRs for PTA achieving a target of 40% T >MIC and 80% T >MIC for Klebsiella spp. following administration of imipenem by all simulated regimens were >90%, except a 0.5 h infusion of 0.5 g q8h and 1 g q8h. All regimens were well tolerated and there were no adverse events.
Discussion
We found that the values of Vd and CL of imipenem were high in serious bacteraemia in immunocompromised patients with febrile neutropenia. A high dosage regimen of a prolonged infusion of 1 g q6h of imipenem may be required for the effective treatment of bacteraemia with pathogens less susceptible to imipenem in this patient population.
Altered pathophysiological conditions in critically ill patients resulting in variations in PK are important factors determining the therapeutic success of antimicrobial agents, particularly hydrophilic antibiotics. For critically ill patients with severe sepsis, the increase of Vd caused by the presence of extensive fluid extravasation as well as enhanced CL result in decreased drug concentrations (15, 16) . Therefore, a higher dosage of antimicrobial agents than standard dose recommendations may be required for coverage of the causative organisms. In addition, a previous study in febrile neutropenic cancer patients showed that the Vd of imipenem was larger, but the CL was lower than in normal volunteers (7). The current study was conducted in life-threatening bacteraemia due to Gram-negative bacilli infections occurring in febrile neutropenic patients, most of whom had a positive fluid balance from administration of large volumes of fluid resuscitation. Moreover, most of these patients also received a number of concomitant medications during the imipenem administration, but none of these drugs affected renal blood flow of the patients. Comparison of the mean ± S.D. PK parameters between the current study and a previous study yielded: Vd, 20.78 ± 1.35 versus 9.41 ± 1.44 and CL, 23.19 ± 1.34 versus 7.95 ± 1.04 l/h (17) . The values of both Vd and total CL of imipenem in these patients were significantly higher than the values obtained from a previous study with healthy volunteers (p < 0.001). Moreover, as compared with the results of PK studies from critically ill patients such as those suffering from burn or ventilator-associated pneumonia, the values of Vd and CL of imipenem in our study were still higher than the values obtained from previous studies (18, 19) . A possible explanation for these results is that patients enrolled in this study had an extensive fluid extravasation and positive fluid balance than those from a previous study, as all patients in this study had both febrile neutropenia and severe bacteraemia with Gram-negative bacilli pathogens. Cilastatin, a renal dehydropeptidase inhibitor, is coadministered in a fixed-drug combination with imipenem in a 1:1 ratio for prevention of the degradation of the imipenem, to protect the kidneys against the toxic metabolite of imipenem. Cilastatin is eliminated by renal clearance, therefore, serious bacteraemia in febrile neutropenic patients may affect its PK, including enhanced renal clearance. However, cilastatin has no intrinsic antimicrobial activity of its own against microorganisms, thus, the therapeutic efficacy of imipenem/cilastatin depends on the activity of imipenem only (1). Imipenem is used effectively as a therapy for severe sepsis in patients with febrile neutropenia (20, 21) . In tropical countries, the stability of imipenem is an important consideration when continuous infusion is to be used (22) and our previous study showed that imipenem remained 91% stable for 4 h at 37 C (unpublished data).
Therefore administration by prolonging the intermittent infusion may offer an opportunity to increase the T >MIC within the limitations of stability at room temperature. A study in a murine thighinfection model has shown that bactericidal activity of carbapenems against E. coli and P. aeruginosa is observed when serum drug concentrations are above the MIC for 40% of the dosing interval (23) . In a previous PD study in patients with pneumonia in an intensive care unit, the high PTA (!90%) for achieving the target of 40% T >MIC was observed at an MIC of 1e2 mg/ml when imipenem was administered by an intermittent 40 min infusion of 1 g q8h, Table 3 Probability of target attainment (PTA) for imipenem regimens achieving 40% T >MIC and 80% T >MIC in 10 febrile neutropenic patients following administration by 0.5-h and 4-h infusions.
MIC (mg/ml) PTA 40% T >MIC PTA 80% T >MIC MIC, minimum inhibitory concentration; T >MIC , time that concentration in tissue and serum are above the MIC; q6h, every 6 h; q8h, every 8 h. whereas a continuous infusion at a total daily dose of 2 g of imipenem had a 90% PTA for achieving the target of 40% T >MIC at an MIC of 2e4 mg/ml (19) . In the current study, a MCS was performed to determine the probability of attaining a specific PD target using various regimens. The results confirmed that the probabilities of 4-h infusion regimens achieving their targets of 40% T >MIC and 80% T >MIC were superior to the probabilities of 0.5-h infusion of imipenem regimens, suggesting that a prolonged infusion is a more efficacious mode of administration of imipenem. The high PTA achieving 40% T >MIC for MIC of 2 mg/ml was observed when imipenem was administered by a prolonged infusion of all regimens.
0.5-h infusion 4-h infusion 0.5-h infusion 4-h infusion
For pathogens with MICs of 4 mg/ml, the high PTA was achieved when the dosage of imipenem was increased to either a 1 g q8h or a 1 g q6h regimen and, moreover, only a 4-h infusion of 1 g q6h regimen achieved >96% PTA of 40% T >MIC . Gram-negative bacilli bacteraemia in immunocompromised patients with febrile neutropenia is a life-threatening infection with a high mortality rate, therefore an appropriate antibiotic therapy and optimum dosing regimen are necessary for maximal bacterial killing. Some experts recommend that for life-threatening infections, antibiotic concentrations should be maintained over the MIC for 66 to 100% of the dosing interval to achieve the maximal antibacterial effect (24, 25) . In a previous clinical study in febrile neutropenic patients conducted to investigate the relationship between the PK/PD index of T >MIC of meropenem and clinical outcomes, the results clearly demonstrated that an optimum clinical response was shown when the percentages of T >MIC of meropenem exceeded 75% of the dosing interval (26) . The clinical breakpoint, as defined by EUCAST, are 2 mg/ml for E. coli, 2 mg/ml for Klebsiella spp, 4 mg/ml for P. aeruginosa and 2 mg/ml for Acinetobacter spp. Our results showed that the high PTAs of achieving 80% T >MIC for MICs of 1 mg/ml and 2 mg/ml were observed when imipenem was administered by 4-h infusions of 0.5 g q6h and 1 g q6h, respectively. Therefore, from these data we recommend that for the treatment of severe sepsis with pathogens less susceptible to imipenem in immunocompromised hosts with altered PK, the imipenem dosage administered by a 4-h infusion should be increased to a maximum of 1 g q6h. However, the MICs of all isolated pathogens in this study were <1 mg/ml, and, after 14 days of treatment, blood cultures were negative in all patients. By using the EUCAST susceptibility patterns to determine the CFR of imipenem for the target of 40%T >MIC , all regimens achieved targets (CFR!90%) against E. coli and Klebsiella spp., whereas for the target of 80%T >MIC , only a 4-h infusion of all regimens and a 0.5-h infusion of 0.5 g q6h and 1 g q6h achieved targets against these pathogens. However, against P. aeruginosa and Acinetobacter spp., no regimens achieved their targets.
This study had some limitations to be considered. First, the PK studies of imipenem in this study were performed at a steady state situation rather than during the early phase of therapy. For critically ill patients with severe sepsis, the increase of Vd from fluid resuscitation during the early phase of antibiotic therapy has more influence on antimicrobial concentrations than at the later steady state. Second, the results of this study could be difficult to extrapolate to other situations because the low body weight of the patients could have had an effect on Vd and CL. Third, the small number of patients could be considered a potential limitation. However, in the absence of data from a larger sample size, a MCS based on a small number of patients such as in this study can be instructive in illuminating the effects of different dosing approaches (27) . Fourth, the CockcrofteGault method used for estimating CL Cr is known to have certain limitations in severely ill and/ or elderly patients (28, 29) .
In conclusion, we found that the values of Vd and CL of imipenem were high in serious bacteraemia in immunocompromised patients with febrile neutropenia. Therefore, for more efficacious treatment of serious infections in this patient population, we recommend a high dosage regimen of a prolonged infusion of 1 g q6h of imipenem may be required.
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